Abstract: Provided herein are methods of using compounds of formula (IA-IF) that are aryl- and heteroaryl-substituted tetrahydroisoquinolines, for the treatment of chronic and neuropathic pain, the treatment and prevention of migraine headache, and the treatment of stress, urge and mixed urinary incontinence.

Abstract: Provided herein are methods of using compounds of formula (1) that are aryl- and heteroaryl-substituted tetrahydroisoquinolines, for the treatment of chronic and neuropathic pain, the treatment and prevention of migraine headache, and the treatment of stress, urge and mixed urinary incontinence.

Abstract: Provided herein are methods of using compounds of formula (IA, IB, IIA, IIB, IIIA, IIIB) that are aryl- and heteroaryl-substituted tetrahydroisoquinolines, for the treatment of chronic and neuropathic pain, the treatment and prevention of migraine headache, and the treatment of stress, urge and mixed urinary incontinence.

Abstract: A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation or an inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of duloxetine, venlafaxine or atomoxetine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a CNS disorder, pain and inflammation, or inflammation-associated disorder suppressing treatment, prevention, or inhibition effective amount of the composition. Compositions and pharmaceutical compositions that contain duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor are also disclosed.

Abstract: A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition provides for treating the subject with reboxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of reboxetine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a CNS disorder and/or pain and inflammation or inflammation-associateed disorder suppressing treatment, prevention, or inhibition effective amount of the composition. Compositions and pharmaceutical compositions that contain reboxetine and a cyclooxygenase-2 selective inhibitor are also disclosed.

Abstract: The present invention concerns the field of urology. The invention provides a novel pharmaceutical composition, comprising a pharmaceutically effective combination of (i) a first compound selected from the group consisting of muscarinic receptor antagonists, 5&agr;-reductase inhibitors, and &agr;-adrenergic receptor antagonists, and precursors and pharmaceutically acceptable salts thereof, and (ii) a second compound selected from the group consisting of 5-HT1a receptor agonists and antagonists, and precursors and pharmaceutically acceptable salts thereof, and optionally a pharmaceutically acceptable carrier or diluent therefor.

Abstract: The present invention concerns the field of urology. The invention provides a novel pharmaceutical composition, comprising a pharmaceutically effective combination of (i) a first compound selected from the group consisting of muscarinic receptor antagonists, 5&agr;-reductase inhibitors, and &agr;-adrenergic receptor antagonists, and precursors and pharmaceutically acceptable salts thereof, and (ii) a second compound selected from the group consisting of 5-HT1a receptor agonists and antagonists, and precursors and pharmaceutically acceptable salts thereof, and optionally a pharmaceutically acceptable carrier or diluent therefor.

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: ##STR1## or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

Abstract: Novel isoxazole isothiazole and pyrazole compounds of the formula: ##STR1## wherein A, R.sup.1, and R.sup.2 are specifically defined, or pharmaceutical salts thereof, are selective and potent cholinergic ligands at neuronal nicotinic receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function, as well as in the treatment of alcohol intoxication and petit real absence epilepsy.

Abstract: Pharmaceutical compositions comprising a therapeutically effective amount of (+) 2-methylpiperidine and a pharmaceutically-acceptable carrier or diluent, as well as to a method of treating cognitive, neurological and mental disorders, which are characterized by decreased cholinergic function in humans and lower mammals, by administration of (+)2-methylpiperidine, optionally with a nicotinic agonist.